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OBJECTIVE — The purpose of this study was to evaluate whether severe hypoglycemia or
intensive therapy affects cognitive performance over time in a subgroup of patients who were
aged 13–19 years at entry in the Diabetes Control and Complications Trial (DCCT).
RESEARCH DESIGN AND METHODS — This was a longitudinal study involving 249
patients with type 1 diabetes who were between 13 and 19 years old when they were randomly
assigned in the DCCT. Scores on a comprehensive battery of cognitive tests obtained during the
Epidemiology of Diabetes Interventions and Complications follow-up study, 18 years later,
were compared with baseline performance. We assessed the effects of the original DCCT treat-
ment group assignment, mean A1C values, and frequency of severe hypoglycemic events on
eight domains of cognition.
RESULTS — There were a total of 294 reported episodes of coma or seizure. Neither fre-
quency of hypoglycemia nor previous treatment group was associated with decline on any
cognitive domain. As in a previous analysis of the entire study cohort, higher A1C values were
associatedwithdeclinesinthepsychomotorandmentalefﬁciencydomain(P0.01);however,
the previous ﬁnding of improved motor speed with lower A1C values was not replicated in this
subgroup analysis.
CONCLUSIONS — Despite relatively high rates of severe hypoglycemia, cognitive function
did not decline over an extended period of time in the youngest cohort of patients with type 1
diabetes.
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R
esults from the Diabetes Control
and Complications Trial (DCCT)
demonstrated that intensive diabe-
tes therapy leading to improved glycemic
control signiﬁcantly reduced the risk of
microvascular, macrovascular, and neu-
ropathic complications (1). Evaluation of
the entire patient group at the end of the
trial (2,3) and again after 12 years of ad-
ditional follow-up with identical compre-
hensivetestbatteriesrevealedthatneither
intensive diabetes therapy nor history of
severe hypoglycemia, which was in-
creased threefold with intensive therapy,
was associated with declines in cognitive
functioning. There was a modest beneﬁt
ofimprovedglycemiccontrolontwocog-
nitive domains: psychomotor and mental
efﬁciency and motor speed (4).
Although severe hypoglycemia did
notappeartoposeanythreattolong-term
cognitivefunctioningintheoverallDCCT
cohort, it is unclear whether episodes of
severehypoglycemiaduringchildhoodor
adolescence would increase the risk of
cognitive decline in those subjects who
entered the DCCT between 13 and 19
years of age. Because of rapid develop-
mentalchangesinthecentralnervoussys-
tem during childhood and adolescence
(5,6), younger brains may be more sus-
ceptible to insults produced by neurogly-
copenia (7). For example, glucose
metabolic rates are not comparable with
those of adults until late adolescence (6).
Indeed, age at time of exposure to meta-
bolic variations of type 1 diabetes could
affect their impact on brain functioning
and cognitive performance. In addition,
there has been debate in the literature as
towhetherthoseinwhomtype1diabetes
is diagnosed in early childhood (8) show
greater cognitive deﬁcits compared with
those patients whose diabetes is diag-
nosed later (9). It has been shown that
children and adults with diabetes diag-
nosed before 7 years of age show mental
and motor slowing (10), visuospatial def-
icits (11), and attentional and executive
dysfunction (12). Although it has been
suggested that episodes of severe hypo-
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tus for these cognitive deﬁcits (11,13), it
is also possible that chronic hyperglyce-
mia during childhood makes the brain
more vulnerable to subsequent brain in-
jury (14). In the current study we ad-
dressed whether hypoglycemic episodes
and/or persistent hyperglycemia during
adolescence has negative consequences
for later cognitive performance in DCCT
patients who were between 13 and 19
years of age on entry in the DCCT.
We addressed whether cognitive de-
clinewasassociatedwith1)assignmentto
intensive versus conventional therapy for
patients who were adolescents during the
DCCT, 2) a history of severe hypoglyce-
mia resulting in coma or seizure, and 3)
theleveloflong-termglycemiccontrol,as
measured by A1C values.
RESEARCH DESIGN AND
METHODS— Between 1983 and
1989, 1,441 subjects with type 1 diabetes
were enrolled in the DCCT. A total of 249
subjects were recruited as adolescents
aged 13–19 years: 32% were 13–14 years
old, 37% were 15–16 years old, and 31%
were17–19yearsold.Alladolescentshad
to be at least Tanner stage II in pubertal
development, which is the stage at which
the ﬁrst signs of puberty are visible on
physicalexamination.Wechoseage19as
the upper age limit, rather than age 18 as
usedinotherstudiesontheDCCTcohort
(15,16),becausethesamplesizewascon-
siderably larger when the age limit was
extended to the ﬁnal year of adolescence.
The DCCT consisted of two cohorts. The
primary prevention cohort (n  149) had
diabetes for 1–5 years, no retinopathy,
and urinary albumin excretion 40
mg/24 h. The secondary intervention co-
hort (n  100) had diabetes for 1–15
years, very mild to moderate nonprolif-
erative retinopathy, and urinary albumin
excretion 200 mg/24 h at baseline. Ap-
proximately half of the adolescent sample
(n  115) was randomly assigned to in-
tensive therapy (three or more insulin in-
jections daily or subcutaneous infusion
with an external pump, guided by fre-
quent self-monitoring of blood glucose)
with preprandial blood glucose level tar-
gets between 3.9 and 6.7 mmol/l, a
monthly A1C target within the nondia-
betic range (6.05%), and a goal of
avoiding hypoglycemia. The remainder
(n  134) was assigned to conventional
therapy with one to two daily insulin in-
jections and no numeric blood glucose
targets but freedom from symptoms of
hyperglycemia and from frequent or se-
vere hypoglycemia as the therapeutic
goal. At the end of the DCCT, this cohort
of patients had been studied for an aver-
age of 7.3 years (range 4–10). Intensive
therapywasrecommendedforallsubjects
because it had been shown to be highly
effective in reducing complications of
long-term diabetes. Subjects in the con-
ventional treatment group were given
training in aspects of intensive therapy
and then returned to their own health
care providers. Between April 2004 and
May 2006, 175 participants (76% of sur-
viving, eligible participants) were reeval-
uated with the cognitive test battery; 74
participants who were adolescents at the
DCCT baseline did not participate in the
Epidemiology of Diabetes Interventions
and Complications (EDIC) follow-up
cognitivetesting.Ofthese,6haddiedand
12 were inactive at the time of testing.
Cognitive test protocol
Cognitive testing, as originally described
for the DCCT (2), was performed at each
site by personnel who were trained and
certiﬁedbytheDCCT/EDICCentralNeu-
ropsychological Coding Unit. The test
protocol is described elsewhere (2,4).
Standardized tests were administered in a
ﬁxedorder.Capillarybloodglucoselevels
were routinely monitored immediately
before testing and at its midpoint to rule
outhypoglycemiaduringtesting.Ifasub-
ject was found to have a blood glucose
level 3.89 mmol/l, testing was stopped
and the patient was given a snack; after
waiting at least 15 min, testing was re-
sumed when the reading returned to at
least 5.0 mmol/l. Tests scoring proce-
dures are described elsewhere (2,4).
Cognitive domains
During the DCCT, 24 test variables were
chosen a priori to be of particular diag-
nosticvaluewhenappliedtopatientswith
type 1 diabetes, and a standardized (Z)
score was calculated for each, with the
mean  SD from the baseline assessment
of the DCCT cohort used as a reference
(2) to provide a unit-free measurement of
the relative improvement or deterioration
in performance compared with the total
group at baseline. Details of the test vari-
ables and domains are described else-
where (4).
Biomedical evaluations and
psychiatric symptoms
During EDIC, subjects completed an an-
nual history, physical examination, elec-
trocardiogram, and laboratory testing,
including serum creatinine and hemoglo-
bin A1C, using the same methods as dur-
ing the DCCT (17). Participants reported
the presence of sensory symptoms of pe-
ripheralneuropathyaspartofneuropathy
screening (18).
Psychiatric symptomatology was
assessedwiththeSymptomChecklist-90-
Revised (SCL-90R), which was adminis-
teredannuallyduringtheDCCTandonce
in the EDIC in the same year that the cog-
nitive testing was performed (19,20). For
this report, the depression scale was used
toassesstheeffectsofmoodoncognition.
Deﬁnition of severe hypoglycemia
During the DCCT, severe hypoglycemia
was deﬁned as any event requiring the
assistance of another individual, includ-
ing seizure or coma, with either blood
glucose2.78mmol/land/orsubsequent
reversal of symptoms with oral carbohy-
drate, glucagon injection, or intravenous
glucose (1). For the purposes of this arti-
cle, severe hypoglycemic events are lim-
ited to those leading to coma and/or
seizure because these episodes are the
most likely to have an impact on cogni-
tion and are most precisely deﬁned. At
quarterly visits, study coordinators asked
about the occurrence of hypoglycemia
since the last visit, and all such events
were reported to the Data Coordinating
Center as soon as possible after their oc-
currence.DuringtheEDIC,theseverehy-
poglycemic events that occurred in the 3
months before the annual visit were doc-
umented on the annual history form, and
further details surrounding these events
were recorded.
Statistical analyses
Demographic and clinical characteristics
were compared with the use of Wilcox-
on’s rank-sum test to evaluate the differ-
ences between the treatment groups for
ordinal and numeric variables (21). The
contingency 
2 test was used for categor-
ical variables; when the sample size was
small, Fisher’s exact test was used (21).
All treatment group comparisons were
based on intention to treat.
Separate analysis of covariance mod-
els were used to assess the effects of treat-
ment group (intensive or conventional),
mean A1C values stratiﬁed by tertiles
(7.9, 7.9–9.5%, and 9.5%), and fre-
quency of severe hypoglycemia (0, 1–5,
and5reportedevents)onthestandard-
ized quantitative score for each of the
eight cognitive domains. Each model ad-
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length of follow-up, visual acuity, self-
reported sensory loss attributable to pe-
ripheral neuropathy, and the number of
interval cognitive tests taken (to control
for practice effects). Results are presented
as the average increase or decrease in the
standardized score from the DCCT base-
line within or between groups or as the
per unit change in a quantitative covari-
ate. Nominally signiﬁcant results (P 
0.01) are cited.
Analyses were repeated to determine
whether cognitive performance was asso-
ciated with 1) current mood state mea-
sured by the SCL-90R depression scores
(scores 63 are suggestive of a possible
depressive disorder), 2) the timing of se-
vere hypoglycemia, and 3) diabetic keto-
acidosis (DKA) during the DCCT.
RESULTS— Table 1 presents the char-
acteristics of the patients at the DCCT
baseline and at the EDIC year-12 follow-
up. There were no statistically signiﬁcant
between-group differences at the DCCT
baseline. The characteristics presented in
Table 1 were also compared between pa-
tients who continued participation in the
EDIC cognitive follow-up and those sub-
jects who were still actively participating
in other EDIC evaluations but did not
participate in the EDIC cognitive evalua-
tion. The only statistically signiﬁcant dif-
ference was severe nonproliferative
diabetic retinopathy at EDIC year 12
(17% participants and 42% nonpartici-
pants). Of the patients who did not par-
ticipate in the EDIC cognitive follow-up,
45% were assigned to intensive treat-
ment. Furthermore, 16 of 38 had severe
nonproliferative diabetic retinopathy,
and 12 of 41 had peripheral neuropathy
at EDIC year 12. No data on these vari-
ables were available for the remaining
nonparticipants.
At EDIC year 12, the age of partici-
pantsrangedfrom29to41years(mean
SD 35.2  2.5 years). Of the participants,
40% reported having completed a college
degree (37% intensive and 42% conven-
tional), and almost 50% reported a pro-
fessional or technical occupation (53%
intensive and 41% conventional). At
EDIC year 12, differences between the
two treatment groups approached signif-
icance for the presence of peripheral neu-
ropathy and severe nonproliferative
diabetic retinopathy (P  0.05).
Over the entire 18-year follow-up,
there were a total of 294 reported epi-
sodes of coma or seizure. Of these, 200
were reported in 51 intensive treatment
group subjects and 94 were reported in
36conventionaltreatmentgroupsubjects
(Table 2).
A separate analysis conducted be-
tween the primary and secondary patient
cohorts differing in terms of diabetes du-
ration and complications revealed no ef-
fect of diabetes duration between these
two groups. Table 3 summarizes the raw
scores for each cognitive test, stratiﬁed by
treatment group. Figure 1 shows cogni-
tive test results for each domain by origi-
naltreatmentgroup(Fig.1A),cumulative
number of severe hypoglycemic events
(0, 1–5, and 5 episodes) (Fig. 1B), and
metabolic control (tertiles of mean A1C
values) (Fig. 1C). Neither original treat-
ment assignment nor cumulative number
of hypoglycemic events inﬂuenced per-
formance in any cognitive domain. Age
did not signiﬁcantly affect cognition. Per-
formance in both sexes improved over
time, and this effect was more pro-
nounced in male participants (P  0.01).
Higher values of A1C were associated
withmodestdeclinesinpsychomotorand
mental efﬁciency (P  0.01). Degree of
self-reported symptoms of depression at
year 12, as indexed by the SCL-90R
(median T score 46.0; scores 63 re-
ﬂect possible depressive disorder), was
Table 1—Characteristics of participants who were adolescents at entry into the DCCT
DCCT baseline
(1983–1989) EDIC year 12 (2005)
Intensive Conventional Intensive Conventional
n 82 93 82 93
Sex (% female) 50 62 50 62
Race (% white) 99 92 99 92
Age (years) 16  21 6  23 6  33 5  3
College graduate (%) 0 0 37 42
Marital status (%)
Never married 100 99 21 19
Married/remarried 0 1 69 68
Separated/divorced/widowed 0 0 10 13
Occupation (%)
Professional/technical 1 0 53 41
Unemployed/retired 0 0 2 9
Severe nonproliferative diabetic
retinopathy (%)
0 0 11 23
Duration (years) 5  35  42 5  42 4  4
A1C† 9.5  1.7 9.4  1.9 7.8  1.5 7.9  1.6
Visual acuity (%)‡ 6 4
Peripheral neuropathy (%)§ 2 1 17 33
Blood pressure
Systolic (mmHg) 112  10 109  11 117  13 115  13
Diastolic (mmHg) 71  97 0  97 4  97 5  9
Treated hypertension 19 30
Lipids
Total cholesterol 166  32 165  31 179  34 185  37
LDL cholesterol 102  30 101  28 109  28 113  30
Lipid-lowering medication 19 17
Current cigarette smoker (%) 9 11 15 18
Symptom Check List-90R
Mean depression T score 45  10 47  11 49  10 49  12
Verbal IQ¶ 110  12 108  12
Full-scale IQ¶ 111  11 110  12
DataaremeansSD.†DCCTbaselinevalueistheeligibilityvalue.‡AtDCCTbaseline,allpatientshadvisual
acuity of 20/32 or better. In EDIC, a Snellen value of 20/40 or worse in at least one eye was recorded. §The
DCCT baseline deﬁnition is pain or numbness in hands only, taken from the Neurological History and
Examinationform.TheEDICdeﬁnitionispainornumbnessinhandsorfeet,takenfromtheAnnualMedical
History and Examination form. Data were not collected in DCCT. ¶Data were not collected in EDIC. Mean
value is 100, with SD of 15. The Wechsler Adult Intelligence Scale was administered for patients aged 16
years(58%intensiveand55%conventional),whereastheWechslerIntelligenceScaleforChildrenwasgiven
for participants aged 16 years (43% intensive and 45% conventional).
Musen and Associates
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on any of the eight domains. Analyses
were repeated using the broader deﬁni-
tion of hypoglycemia, which includes ep-
isodes in which the patient has incapacity
sufﬁcient to require assistance. The re-
sults with the broad deﬁnition were sim-
ilar to those obtained using the narrow
deﬁnition (i.e., restricted to seizure or
coma).
The timing of severe hypoglycemic
events did not affect performance on any
of the eight cognitive domains. We found
that 47 patients reported their ﬁrst epi-
sode of coma or seizure during adoles-
Table 2—Severe hypoglycemic events (coma/seizure) among participants who were adolescents at entry into the DCCT
DCCT EDIC Total follow-up
Intensive Conventional Intensive Conventional Intensive Conventional
n 82 93 82 93 82 93
Events
0 3 5 7 26 16 7 3 1 5 7
1–5 39 17 20 26 40 31
5* 8 4 1 0 11 5
Total patients with 1 event 47 21 21 26 51 36
Total events 155 53 45 41 200 94
All DCCT hypoglycemic events were documented. EDIC hypoglycemic events were documented in the 3-month period before the annual visit. *Number of events
ranged from 1 to 18 in the intensive group and 1 to 11 in the conventional group.
Table 3—Raw cognitive test scores
DCCT baseline (1983–1989) EDIC year 12 (2005)
Intensive Conventional Intensive Conventional
n 82 93 82 93
Problem solving
Similarities* 12.2  2.8 12.1  2.5 13.8  2.2 13.1  2.4
Category test (no. errors)† 30.7  18.2 32.3  22.9 15.0  10.8 14.9  12.9
Learning
Symbol-digit learning (no. correct) 24.5  4.3 24.5  4.5 25.7  2.9 24.8  4.4
Tactual performance memory (no. correct) 7.4  1.5 7.3  1.7 8.1  1.2 7.8  1.5
Immediate memory
Visual reproductions (no. correct) 14.6  1.9 14.5  2.4 15.3  1.5 15.1  1.7
Short-term memory (no. correct) 38.0  9.5 37.5  10.2 42.7  11.0 40.1  11.8
Logical memory (no. correct) 19.7  5.7 19.5  5.4 20.9  8.5 20.0  5.3
Digit symbol (no. correct) 8.4  1.0 8.1  1.4 8.0  1.6 7.9  1.5
Delayed recall
Visual reproductions (no. correct) 15.5  1.5 15.4  1.7 15.5  1.4 15.3  1.7
Logical memory (no. correct) 15.9  5.2 16.3  5.2 18.4  8.9 17.9  8.0
Spatial information
Embedded ﬁgures (time in s)† 7.4  3.2 7.0  2.6 5.5  2.6 5.3  2.2
Object assembly* 11.5  2.6 12.0  2.8 14.5  2.5 14.2  2.7
Block design* 12.6  2.4 12.1  2.8 14.1  2.4 13.8  2.8
Tactual performance test (time in min) † 10.7  3.8 10.9  3.4 8.6  3.1 9.4  3.0
Attention
Digit vigilance (time in s)† 398.8  77.9 401.5  91.2 365.2  80.0 386.1  84.6
Digit vigilance (no. errors)† 6.0  5.7 6.4  5.6 5.4  6.1 6.2  6.2
Digit span* 11.1  3.0 11.1  2.7 12.2  2.8 11.8  3.1
Psychomotor and mental efﬁciency
Verbal ﬂuency (no. correct) 37.8  9.3 37.4  10.4 48.8  12.7 45.6  13.6
Digit symbol, 90-s total (no. correct) 62.4  13.1 60.2  11.4 67.8  10.5 66.3  9.1
Trail making, part B (time in s)† 51.3  16.6 51.9  16.2 45.6  12.8 48.9  15.1
Grooved peg test, dominant hand (time in s)† 66.4  10.4 66.9  9.4 66.0  11.3 66.9  13.0
Grooved peg test, nondominant hand (time in s)† 71.0  10.7 72.8  12.3 72.0  12.2 74.4  17.8
Motor speed
Finger tapping, dominant hand (no. taps in 10 s) 46.0  6.9 45.0  6.4 52.1  7.1 50.6  7.1
Finger tapping, nondominant hand (no. taps in 10 s) 43.0  6.4 41.7  5.8 46.9  5.9 44.5  7.1
Data are means SD. *Scaled scores. †Higher scores indicate poorer performance.
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reported having lost consciousness be-
tween one and ﬁve times before their
DCCT baseline evaluation. Further, there
was no synergistic effect of hypoglycemia
and hyperglycemia on cognition. Patients
who experienced DKA (n  26) during
the DCCT (ages 13–19 years) declined in
cognitive performance on the learning
domain, whereas the patients without
DKA improved. Further, patients with
DKA episodes during the DCCT im-
provedlessonthespatialinformationdo-
main than patients with no DKA events
(data not shown).
CONCLUSIONS— Our previous re-
port on the entire DCCT/EDIC cohort
showednodetrimentaleffectsofintensive
treatment or severe hypoglycemic epi-
sodes on cognitive performance (4).
However,becauseofthepotentialvulner-
ability of the developing brain (14), we
evaluated whether intensive treatment
during adolescent years posed threats to
long-term cognitive functioning. Severe
hypoglycemic episodes during childhood
are a major concern, especially given the
ﬁndings that cognitive deﬁcits may be
more common in those in whom type 1
diabetes is diagnosed during childhood
(9,12,22). Moreover, children may be
more sensitive than adults to even mod-
estly lower glucose levels, with cognitive
deterioration at 3.3 versus 2.5 mmol/l
in adults (23).
Our results closely resemble those pre-
viously reported for the entire cohort (4).
Intensive treatment is not associated with
risk for long-term cognitive dysfunction,
even in the subset of patients who entered
the DCCT during adolescence. As with the
ﬁndings from the entire cohort, we found
thathigherA1Cvalueswereassociatedwith
poorer performance on measures of psy-
chomotor and mental efﬁciency, which re-
quiretheintegrationofmotorandcognitive
processes. This ﬁnding further highlights
the beneﬁts of intensive glycemic control.
Higher A1C values were also associated
with somewhat slower performance on a
simple measure of motor speed (Fig. 1),
but,unlikeourearlierresultswiththeentire
cohort, that effect failed to reach statistical
signiﬁcance in this cohort, possibly due to
smaller sample size. Although we collected
data on retinopathy, which are associated
with higher A1C levels, the effect that this
complication has on cognitive ability is be-
yond the scope of the article and will be
addressed separately.
Despitenodiscernibleilleffectsoncog-
nition as a result of severe hypoglycemia,
brainabnormalitiesduetoserioushypogly-
cemia have been observed in other studies.
For example, children with a history of se-
vere hypoglycemia have shown some ab-
normalities in brain structure and function
(22). Slow-wave electroencephalographic
activity is increased in this patient popula-
tion, especially in the frontal regions (24),
whichgovernexecutivefunctionandatten-
tion. Finally, recent evidence has suggested
that severe hypoglycemia in children alters
graymatterdensity(22),analogoustowhat
hasbeenreportedinyoungadultswithtype
1 diabetes (25). There is not always a direct
relationshipbetweenbrainchangesandbe-
havioral effects. Thus, although no notable
cognitivedeﬁcitswereobserved,theseearly
brain changes may serve as a marker of fu-
ture cognitive impairments (25).
Although our conclusion from this
study is that severe hypoglycemic episodes
Figure1—ChangesincognitivedomainsbetweenDCCTbaselinecognitivetestingandfollow-up
testing (mean of 18 years after baseline) based on change in Z scores for intensive ( ) vs.
conventional (f) treatment groups (A), frequency of severe hypoglycemia (coma or seizure)
episodes (no episodes  , 1–5 espisodes o,o r5 episodes f)( B), and tertiles of mean A1C
(7.9%  , 7.9% o,o r9.5% f)( C). 1, Problem solving; 2, learning; 3, immediate memory;
4,delayedrecall;5,spatialinformation;6,attention;7,psychomotorandmentalefﬁciency;and8,
motor speed. ANCOVA models were used with adjustments for baseline age, sex, years of educa-
tion, length of follow-up, visual acuity, self-reported sensory loss due to peripheral neuropathy,
and the number of interval cognitive tests taken. Neither treatment group nor cumulative number
of hypoglycemic episodes inﬂuenced performance in any cognitive domain. Higher values of A1C
were associated with modest declines in psychomotor and mental efﬁciency (P  0.01).
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whenexperiencedduringadolescence,sev-
eralstudylimitationsneedtobeconsidered.
First,weincludedpatientsbetweentheages
of 13 and 19 years; therefore, we cannot
determine whether diabetes or hypoglyce-
mia during early childhood is associated
with cognitive deﬁcits later in life. Accord-
ingly, we have limited information on the
effects of diabetes on the very young brain.
Second, the results must be generalized
cautiously not only because the sample size
of our cohort is relatively small but also be-
causeofthecarefulselectioncriteriaapplied
to subjects recruited into the DCCT. Third,
ourstudyimposedrestrictionsonthenum-
ber and severity of DKA and hypoglycemic
episodes that patients could experience
during the several years before the DCCT.
These exclusionary factors restrict our abil-
ity to comment on whether long-term cog-
nition is further affected in patients who
experienced these particularly serious met-
abolic consequences of diabetes.
In summary, our study indicates that
with regard to long-term cognitive func-
tion, intensive treatment is safe for pa-
tientswhohadthediagnosisofdiabetesas
children, despite the increased threat of
severe hypoglycemic episodes. Neverthe-
less, we need to remain cognizant of the
dangers of acute hypoglycemia, which
can lead to comas, accidents, injuries,
death,familystress,lossofschoolorwork
time,andlossofcommitmenttothegoals
of intensive treatment. Thus, continued
research is needed to develop new thera-
pies and technologies that will minimize
or eliminate this major obstacle to
achievement of optimal control of type 1
diabetes.
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